September 30, 2022Open Access

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases

SSSiddharth SinghBennett University AIAske Thorn IversenNovo Nordisk (Denmark)KAKristine H. AllinUniversity of Copenhagen

Key Points

Key points are not available for this paper at this time.

Abstract

In this comparative effectiveness study of older patients with IBD, vedolizumab was associated with a higher risk of treatment failure compared with TNF antagonists, particularly among patients with Crohn disease, without offering a significant safety advantage.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Singh et al. (Fri,) studied this question.

synapsesocial.com/papers/69d8b1b78c03fbaff8befdfb https://doi.org/https://doi.org/10.1001/jamanetworkopen.2022.34200

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Perguntar à IA

Bookmark

View Full Paper